Otonomy Reports Third Quarter 2020 Financial Results and Provides Corporate Update - GlobeNewswire
Enrollment completed in Phase 3 clinical trial of OTIVIDEX ® in Ménière’s disease with results expected in the first quarter of 2021 Positive results reported for Phase 1/2 clinical trial of OTO-313 in tinnitus patients Enrollment completed in Phase 1/2 clinical trial of OTO-413 in hearing loss with results expected by end of year Public offering completed for total gross proceeds of $69.1 million Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2020 and provided an update on its product pipeline and corporate activities. The company will host a conference call and webcast today at 4:30 p.m. ET to discuss recent highlights and financial results. “We have continued to successfully execute our business plan by completing patien...